Dr. Andreas Varkaris, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 111
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 264340 -
Student in an Organized Health Care Education/Training Program
MA license 264340
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Massachusetts General Hospital Boston, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 111
- Services billed
- 471
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 198 | 62 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 36 | 13 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 32 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $893,943 in research payments for these studies, mostly to the institutions running them.
- A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
Beone Medicines Ltd. · Terminated · NCT05381909 - Open-label dose-finding trial to explore safety, pharmacokinetics, pharmacodynamics, and efficacy of BI 3706674 given orally as monotherapy in patients with unresectable metastatic KRAS wild type amplified gastric, oe…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase Ia/Ib Study of the Combination of the FGFR inhibitor Pemigatinib and the EGFR inhibitor Afatinib in AdvancedRefractory Advanced Solid Tumors
Incyte Corporation - FIH trial in gastric and esophageal cancer
Boehringer Ingelheim Pharma GmbH & Co.kg - Open-label dose-finding trial to explore safety, pharmacokinetics, pharmacodynamics, and efficacy of BI 3706674 given orally as monotherapy in patients with unresectable metastatic KRAS wild type amplified gastric, oe…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.